Zaleplon (Sonata)

Sedative-Hypnotic - Nonbenzodiazepine Z-Drug

Overview

Zaleplon is a nonbenzodiazepine sedative-hypnotic medication from the pyrazolopyrimidine class that was approved by the FDA in 1999. It is the shortest-acting of all the Z-drugs, with an ultrashort elimination half-life of approximately 1 hour and rapid onset of action within 30 minutes. Zaleplon is primarily indicated for the short-term treatment of insomnia, specifically for patients who have difficulty falling asleep (sleep onset insomnia). Its unique pharmacokinetic profile allows for middle-of-the-night dosing when at least 4 hours of sleep time remain, making it particularly useful for patients who experience early morning awakenings or need flexibility in dosing timing.

Mechanism of Action

Zaleplon acts as a high-selectivity, high-affinity positive allosteric modulator of GABAA receptors at benzodiazepine binding sites. It binds preferentially at α1-containing GABAA receptors (BZ1/Ω1 receptors), which primarily mediate the sedative effects of benzodiazepines. Unlike zolpidem, zaleplon also binds with appreciable affinity to some α2 and α3-containing GABAA receptors, which are implicated in anxiolytic and muscle relaxant effects. Despite this broader binding profile, zaleplon demonstrates greater selectivity at these sites than lorazepam or zopiclone. The medication enhances the activity of GABA, the brain's primary inhibitory neurotransmitter, slowing brain activity to promote sleep initiation while preserving normal sleep architecture.

Indications

  • Insomnia: FDA-approved for the short-term treatment of insomnia in adults, specifically for difficulty falling asleep (sleep onset insomnia). Indicated for use up to 30 days in controlled clinical trials.
  • Middle-of-the-Night Awakenings: Can be administered for nighttime awakenings when at least 4 hours of sleep time remain.
  • Situational Insomnia: Jet lag, shift work sleep disorder, or acute stress-related sleep disturbances.
  • Sleep Maintenance: Limited evidence for modified-release formulations for sleep maintenance insomnia.
  • Aviation Medicine: Approved by Federal Aviation Administration and U.S. Air Force as a "no-go pill" for aviators (with specific restrictions).

Dosing and Administration

Patient Population Starting Dose Usual Dose Maximum Dose
Adults (Non-elderly) 10 mg at bedtime 10 mg at bedtime 20 mg at bedtime
Low Weight Individuals 5 mg at bedtime 5 mg at bedtime 10 mg at bedtime
Elderly (≥65 years) 5 mg at bedtime 5 mg at bedtime 10 mg at bedtime
Debilitated Patients 5 mg at bedtime 5 mg at bedtime 10 mg at bedtime
With Cimetidine 5 mg at bedtime 5 mg at bedtime 10 mg at bedtime
  • Timing: Take immediately before bedtime or after getting into bed when experiencing difficulty falling asleep.
  • Middle-of-Night Dosing: Can be taken during the night if at least 4 hours of sleep time remain before arising.
  • Food Effects: Take on an empty stomach; high-fat meals delay absorption and reduce effectiveness.
  • Onset: Effects begin within 30 minutes; plan to remain in bed for 7-8 hours.
  • Hepatic Impairment: Mild-moderate: use with caution; Severe: contraindicated due to significantly increased exposure.
  • Renal Impairment: No dose adjustment needed for any degree of renal impairment.
  • Elderly: Start at 5 mg due to increased sensitivity and fall risk.
  • Pregnancy: Limited safety data; use only if potential benefit justifies potential risk.
Clinical Pearl: Zaleplon's ultrashort half-life (1 hour) makes it unique among hypnotics - it can be taken in the middle of the night without significant next-day impairment, provided at least 4 hours of sleep remain.

Pharmacokinetics

Parameter Details
Absorption Rapidly absorbed; peak concentration in approximately 1 hour
Bioavailability Absolute bioavailability approximately 30% due to significant first-pass metabolism
Metabolism Primarily by aldehyde oxidase (major pathway); CYP3A4 (minor, ~9%)
Half-Life Approximately 1 hour (ultrashort); no active metabolites
Protein Binding Approximately 60%
Excretion Urine (~70% as metabolites, <1% unchanged); feces (~17%)
Clinical Pearl: Zaleplon's metabolism by aldehyde oxidase (rather than primarily CYP enzymes) results in fewer drug interactions compared to other Z-drugs. Psychomotor impairment typically resolves within 2-4 hours post-dose.

Side Effects

  • Central Nervous System: Dizziness, headache, drowsiness, amnesia, somnolence
  • Gastrointestinal: Nausea, abdominal pain, dyspepsia
  • General: Weakness, malaise, fever, photosensitivity
  • Sensory: Eye pain, tingling, altered taste, parosmia
  • Other: Menstrual pain (in women), myalgia

Note: Next-day somnolence is less common with zaleplon compared to other hypnotics due to its short half-life.

  • Complex Sleep Behaviors: Sleep-walking, sleep-driving, eating, making phone calls while not fully awake - FDA Boxed Warning
  • Memory Loss: Anterograde amnesia, particularly with doses >10 mg or when insufficient sleep time
  • Psychiatric Effects: Worsening depression, suicidal thoughts, hallucinations, abnormal thinking
  • Respiratory Depression: Risk increased when combined with other CNS depressants
  • Allergic Reactions: Anaphylaxis, angioedema; contains tartrazine (FD&C Yellow #5) which may cause allergic reactions
  • Dependence/Withdrawal: Physical and psychological dependence, rebound insomnia upon discontinuation
Clinical Pearl: Zaleplon causes less next-day impairment than other Z-drugs due to its ultrashort half-life, but complex sleep behaviors remain a serious concern requiring immediate discontinuation if they occur.

Interactions

  • CYP3A4 Inhibitors: Cimetidine (reduce dose to 5 mg), ketoconazole, erythromycin may increase zaleplon levels
  • CYP3A4 Inducers: Rifampin, phenytoin, carbamazepine, phenobarbital can reduce zaleplon effectiveness
  • CNS Depressants: Additive effects with alcohol, benzodiazepines, opioids, antihistamines, antipsychotics
  • Thioridazine: Additional sedation observed; unclear if true drug interaction or additive effect
  • No Significant Interactions: Diphenhydramine (weak aldehyde oxidase inhibitor), ibuprofen, digoxin
  • Alcohol: Contraindicated - significantly increases sedation and psychomotor impairment
Clinical Pearl: Unlike other Z-drugs, zaleplon's primary metabolism by aldehyde oxidase results in fewer clinically significant drug interactions, but CNS depressant combinations remain dangerous.

Contraindications and Warnings

  • Hypersensitivity: Known hypersensitivity to zaleplon or any component; includes tartrazine sensitivity
  • Complex Sleep Behaviors: History of complex sleep behaviors after taking zaleplon
  • Severe Hepatic Impairment: Significantly reduced clearance and increased exposure
  • Complex Sleep Behaviors: FDA Boxed Warning - can result in serious injuries or death
  • CNS Depression: Impairs mental and physical capabilities; avoid driving until effects known
  • Abuse/Dependence Potential: Schedule IV controlled substance; monitor for misuse
  • Withdrawal: Gradual tapering recommended; rebound insomnia may occur
  • Respiratory Conditions: Use caution in COPD, sleep apnea, or compromised respiratory function
  • Mental Health: May worsen depression; monitor for suicidal ideation
  • Elderly Patients: Increased risk of confusion, dizziness, and falls

Evidence and Guidelines

  • Sleep Onset Efficacy: Studies demonstrate reduced sleep latency at 5, 10, and 20 mg doses compared to placebo
  • 35-Night Study: No significant increase in wakefulness during last quarter of night compared to placebo
  • Elderly Populations: 628 patients ≥65 years studied; 5 mg dose effective with good tolerability
  • Psychomotor Function: Impairment present at 1 hour post-dose but resolved by 2-4 hours
  • No Tolerance: Studies up to 28 nights showed no evidence of tolerance development
  • Driving Studies: No significant impairment in driving performance when adequate sleep time allowed
  • AASM Guidelines: 2017 Clinical Practice Guideline recommended zaleplon specifically for sleep-onset insomnia
  • Beers Criteria: Listed as potentially inappropriate medication in elderly due to fall risk and cognitive effects
  • Aviation Medicine: FAA allows use with 12-hour wait period and maximum twice weekly
  • Military Use: U.S. Air Force approves as "no-go pill" with 4-hour flight restriction
  • Duration Guidance: Generally recommended for short-term use (1-2 weeks), maximum 30 days in studies

Monitoring Parameters

  • Sleep Response: Monitor sleep latency, ability to fall asleep, and early morning awakenings
  • Complex Sleep Behaviors: Screen for episodes of sleep-walking, sleep-driving, or other unconscious activities
  • Next-Day Function: Assess for residual sedation, cognitive impairment, or psychomotor effects
  • Mental Status: Monitor for mood changes, depression, suicidal ideation, or abnormal behaviors
  • Abuse/Dependence: Watch for signs of tolerance, dose escalation, or drug-seeking behaviors
  • Fall Risk: Particularly important in elderly patients; assess balance and coordination
  • Treatment Duration: Regular reassessment of continued need; generally limit to short-term use
  • Respiratory Function: Monitor in patients with respiratory conditions or sleep apnea

Patient Education

  • Timing Flexibility: Can take at bedtime or in middle of night if at least 4 hours of sleep remain
  • Empty Stomach: Take without food for best effectiveness; high-fat meals delay onset
  • Rapid Onset: Effects begin within 30 minutes; be prepared for sleep immediately
  • Complex Sleep Behaviors: Report any activities performed while not fully awake to healthcare provider immediately
  • Alcohol Prohibition: Never combine with alcohol due to dangerous additive effects
  • Driving Caution: Do not drive until you know how the medication affects you; generally safe after 4+ hours
  • Storage Security: Keep in secure location due to controlled substance status and abuse potential
  • Tartrazine Allergy: Contains yellow dye that may cause allergic reactions in sensitive individuals
  • Short-Term Use: Intended for brief treatment periods; discuss continued need with provider
  • Emergency Situations: Seek immediate help for allergic reactions, breathing difficulties, or complex sleep behaviors